NewsPronto

 
The Times


.

ACN Newswire

Read more press releases from ACN Newswire here

Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting

  • Written by ACN Newswire

image

image
- Very good safety profile with no AEs and SAEs related to NBTXR3- Complete Response achieved in 3 out of 7 patients evaluable and partial response achieved in 3 out of 7, among 10 patients treated- Third indication in global NBTXR3 development confirming transferability across different cancers

Paris, France and Cambridge, Massachusetts, USA,...

Read more: Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the...